New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - adrenaline acid tartrate 1:80000; lidocaine hydrochloride 2%;   - solution for injection - 2 % - active: adrenaline acid tartrate 1:80000 lidocaine hydrochloride 2%  

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - adrenaline acid tartrate 1:100000; lidocaine hydrochloride 2%;   - suspension for injection - 2 % - active: adrenaline acid tartrate 1:100000 lidocaine hydrochloride 2%  

New Zealand - English - Medsafe (Medicines Safety Authority)

ivoclar vivadent ltd - adrenaline acid tartrate 10 µg/ml;  ;  ; articaine hydrochloride 40 mg/ml;   - solution for injection - 40mg/10µg per ml - active: adrenaline acid tartrate 10 µg/ml     articaine hydrochloride 40 mg/ml   excipient: sodium chloride sodium hydroxide sodium metabisulfite water for injection - septanest 1:100,000 is indicated for local or regional anaesthesia for both simple and complex dental procedures in adults, adolescents and children 4 years of age and older. septanest 1:100,000 is indicated only for dental procedures.

New Zealand - English - Medsafe (Medicines Safety Authority)

biomed limited - adrenaline acid tartrate 0.18%{relative}; lidocaine hydrochloride monohydrate 4%{relative}; tetracaine hydrochloride 0.5%{relative} - topical solution - active: adrenaline acid tartrate 0.18%{relative} lidocaine hydrochloride monohydrate 4%{relative} tetracaine hydrochloride 0.5%{relative} excipient: sodium metabisulfite water for injection - topicaine is intended for use in adults and children older than 1 year, as a topical anaesthetic pain management when repairing wounds, particularly facial or scalp wounds.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - adrenaline acid tartrate 1:200000; lidocaine hydrochloride 1.5%;   - solution for injection - 1.5 % - active: adrenaline acid tartrate 1:200000 lidocaine hydrochloride 1.5%  

United Kingdom - English - myHealthbox

farma mediterrania s.l. - noradrenaline tartrate - concentrate for solution for infusion - 2mg/ml - adrenergic and dopaminergic agents - noradrenaline (norepinephrine) concentrate is indicated for the emergency restoration of blood pressure in cases of acute hypotension.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - brimonidine tartrate, quantity: 2 mg/ml; timolol maleate, quantity: 6.8 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; purified water; hydrochloric acid - combigan eye drops are indicated for the reduction of elevated intraocular pressure for treatment of open angle glaucoma and/or ocular hypertension, in patients not adequately responding to monotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - adrenaline (epinephrine) acid tartrate, quantity: 18.2 microgram/ml (equivalent: adrenaline (epinephrine), qty 10 microgram/ml); lidocaine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide; sodium metabisulfite - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques; infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml); adrenaline (epinephrine) acid tartrate, quantity: 9.1 microgram/ml (equivalent: adrenaline (epinephrine), qty 5 microgram/ml) - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; hydrochloric acid; sodium chloride - indications as at 4 april 2000: marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia; epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia; continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dechra veterinary products (australia) pty. ltd. - bupivacaine hydrochloride; lignocaine as lignocaine hydrochloride; adrenaline-l-acid tartrate-d; cetrimide - topical cream, ointment, paste, gel, lotion - bupivacaine hydrochloride anaesthetic active 4.2 g/l; lignocaine as lignocaine hydrochloride anaesthetic active 40.6 g/l; adrenaline-l-acid tartrate-d hormone active 24.8 mg/l; cetrimide ammonium-quaternary active 5.0 g/l - anaesthetics/analgesics - lamb with mulesing wound - post surgical pain